Latest Conference Articles

Renata Block, MMS, PA-C, shares her favorite topics from the aesthetic conference held last month.

Dozens of investigators shared findings to advance care in patients with melanoma during Mohs micrographic surgery.

Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.

López-Ferrer discussed how to achieve well-being for patients with psoriasis and Koscielny discussed the unique topics of the Skin Academy.

Hasbargen presented Mohs surgery pearls on closure types and pattern recognition at the 2024 Diversity in Dermatology meeting.

Blackburn presented integrative medicine pearls on gut and hormone health at the 2024 Diversity in Dermatology meeting.

Scurto presented integrative medicine pearls at the 2024 Diversity in Dermatology meeting.

Miranti presented tips on handling denial hurdles and how to ensure patients receive access to the treatments they need.

Three distinct congresses known as RAVE (Revolutionizing Atopic Dermatitis, Alopecia Areata, and Vitiligo) will be held June 8-10, in Chicago, Illinois.

Paller shares early findings from the award winning poster on PEDISTAD trial and its clinical implication for children with atopic dermatitis.

Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.

Catch up on late-breaking research shared at the 2024 American Academy of Dermatology Annual Meeting.

Spizuoco shares pearls from her sessions, "Infectious Diseases: The Story Behind STDs," and "Everything You Need to Know About Dermatopathology and the Dermatopathologist," from the Diversity in Dermatology conference.

Henry Lim, MD, shares insights on JAK inhibitor safety and the poster presented at the AAD Annual Meeting

"It's an exciting time" in dermatology, said Lee, who reflects on late-breaker data and other research presented at the 2024 AAD Annual Meeting.

We've compiled all our coverage from the biggest dermatology meeting of the year to give you a thorough recap of everything you need to know or catch up on.

Allergist immunologist Giselle Mosnaim, MD, recently spoke with Dermatology Times to discuss late-breaking phase 3 REMIX-1 and REMIX-2 data presented at the American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Ahead of the next 3 months of the year, Dermatology Times wants to know what conferences and meetings you plan to attend between April and June. Share your thoughts with us by March 27.

Catch up on coverage from the fifth and final day of the 2024 American Academy of Dermatology Annual Meeting.

Founder Dina El-Sherif, MBA, gave an in-depth overview of the at-home facial rejuvenation device and its 3-step process at AAD 2024.

In between sessions, Lal shared his favorite pearls from AAD, a recent challenging pediatric case in his practice, the significance of LinkedIn, and more.

Kim, who received the Marion B. Sulzberger Award at the 2024 American Academy of Dermatology Annual Meeting, discussed itch research an implications for clinical practice.

Arianne Shadi Kourosh, MD, MPH, FAAD, shared pearls on environmental factors that can impact skin aging and pigmentation including visible light, IR radiation, location, and pollution.

Rebecca Hartman, MD, MPH, FAAD, and Christine Kannler, MD, FAAD, took a deep dive into considerations and pearls to treat patients who have been exposed to extreme heat and chemicals in the line of duty.

Raj Chovatiya, MD, PhD, delves into the conditions that could be red, itchy, and not atopic dermatitis. He explains the importance of knowing characteristics for various inflammatory conditions.

The Bristol Myers Squibb-hosted event brought together a panel of leading women in dermatology to discuss the challenges they’ve faced and how women can support each other.

Frey discussed the role of various cosmeceuticals and ingredients in benefitting the skin health of patients, as well as insights into pairing OTC products with Rx.

Shawn Kwatra, MD, shares positive updates on phase 2 oral povorcitinib for prurigo nodularis at AAD 2024.